liuxiangqin liuxiangqin
Journal of Microbes and Infections.
2025, 20(4):
208-216.
Abstract: objective:To investigate the trends in resistance rates of Enterobacteriaceae bacteria and analyze the carbapenemase genes blaNDM and blaKPC as well as resistant genes. Methods: This study included 700 patients with Enterobacteriaceae bacterial infections treated at our hospital from January 2017 to December 2023. Among them, 350 patients with Enterobacteriaceae bacterial infections who met the criteria of the Clinical and Laboratory Standards Institute (CLSI) 2015 edition were selected as the study group, and 350 non-resistant patients were selected as the control group. The risk factors for resistance of Enterobacteriaceae bacteria, trends in resistance rates, the resistance situation of Enterobacteriaceae bacteria, and the distribution of resistance genes were analyzed. Results:Statistical significance was observed in the differences between the study group and the control group in terms of hypertension (χ2=57.461, P=0.000), diabetes (χ2=5.079, P=0.024), hyperlipidemia (χ2=7.451, P=0.007), chronic obstructive pulmonary disease (χ2=47.801, P=0.000), duration of hospitalization (t=66.029, P=0.000), APACHE II score (t=59.462, P=0.000), duration of mechanical ventilation (t=70.986, P=0.000), types of antibiotics used (t=37.951, P=0.000), endotracheal intubation (χ2=8.721, P=0.003), urinary catheterization (χ2=16.641, P=0.000), use of glucocorticoids (χ2=6.091, P=0.014), and albumin levels (t=104.655, P=0.000) (P>0.05). Refer to Table 1 for details. Multifactorial analysis revealed that hypertension (OR=0.313), diabetes (OR=0.320), hyperlipidemia (OR=0.299), chronic obstructive pulmonary disease (OR=0.362), duration of hospitalization (OR=0.339), APACHE II score (OR=0.351), duration of mechanical ventilation (OR=0.345), types of antibiotics used (OR=0.303), endotracheal intubation (OR=0.349), urinary catheterization (OR=0.359), use of glucocorticoids (OR=0.339), and albumin levels (OR=0.318) were all identified as risk factors for Enterobacteriaceae bacterial resistance in patients.Analysis of the trends in Enterobacteriaceae bacterial resistance in the respiratory department, intensive care unit, and neurology department from 2017 to 2023 showed a significant upward trend in the respiratory department (χ2=14.307, P=0.000), intensive care unit (χ2=17.864, P=0.000), and neurology department (χ2=13.763, P=0.000). Analysis of Enterobacteriaceae bacterial resistance revealed resistance primarily to ceftriaxone, ciprofloxacin, levofloxacin, piperacillin, and